Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00445146
Status:
COMPLETED
Last Update Posted:
2016-04-25
First Post:
2007-02-28
Brief Title:
Safety of EVGRTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Study Overview
Official Title:
A Phase 2 Open-Label Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 GS-9137r Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subjects
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of this study is to observe the long-term safety of elvitegravir EVG boosted with ritonavir RTV in combination with other antiretroviral ARV agents in participants who have completed a prior EVGRTV treatment study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None